Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Use of Eprex in Canada

Carole Légaré, Christopher Turner and Anges V. Klein
CMAJ September 14, 2004 171 (6) 552-553; DOI: https://doi.org/10.1503/cmaj.1041010
Carole Légaré
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Turner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anges V. Klein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2004 Canadian Medical Association or its licensors

We are writing to correct and clarify several points in Barbara Sibbald's article on recombinant human erythropoietin (epoetin alfa [Eprex]).1 Sibbald erroneously states that Health Canada has advised practitioners “against intravenous injection” of the drug “for patients with chronic renal failure.” In fact, Health Canada's advisory of Jan. 13, 2004, recommended that “where intravenous access is available, Eprex HSA-[human serum albumin] containing formulation should be administered intravenously”; where intravenous access is not available, the HSA-containing formulation may be administered subcutaneously but only after a risk–benefit assessment.2 These guidelines for the use of Eprex in Canada are detailed in the text box.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

Sibbald correctly communicated the well-documented risk of pure red cell aplasia (PRCA) associated with the use of Eprex but failed to note that the degree of risk differs with the formulation and route of administration. Two formulations are available in Canada, one containing HSA as the stabilizer, the other containing polysorbate-80 (i.e., HSA-free [not “HSA-3,” as mentioned in the CMAJ article]). The latter has recently been presented in a prefilled syringe intended for subcutaneous administration, whereas the formulation containing HSA is presented in multiuse vials. Most cases of PRCA are associated with HSA-free Eprex administered subcutaneously (this route is associated with increased development of antibodies to an immunogen3). We are not aware of any domestic or foreign reports of PRCA associated with Eprex administered intravenously.

In Europe, Eprex is available only in the HSA-free formulation. Furthermore, contraindications are not absolute in Europe, so use of a “contraindicated” product is not actually prohibited. Therefore, it was appropriate for the European Medicines Agency to issue an advisory to health care practitioners contraindicating HSA-free Eprex in Europe, given the concern over PRCA with this formulation and the lack of an alternative. In Canada, health care professionals have access to an alternative Eprex formulation (containing HSA and not polysorbate-80), so a “ban” on the product is not appropriate.

Sibbald also stated that Eprex has been banned in Australia. However, a “Dear Healthcare Professional” letter, issued by the sponsor in December 2002, recommends “that Eprex be given by the intravenous route where feasible, as this is thought to reduce the risk of antibody formation.”4 Therefore, to date, Eprex has not in fact been banned by the Australian Therapeutic Goods Administration.

It should also be noted that PRCA is not always irreversible; only 25% to 50% of patients become transfusion-dependent, and immunosupressive therapy can be effective in treating the condition.3

An alternative erythropoietin has not been on the Canadian market for long, and therefore the cumulative safety data are less extensive than for older products such as Eprex. In addition, many patients who currently take the newer product have also been exposed to Eprex. The limitation of assessing products that are relatively new to the market, on a background of exposure to another similar product, must be weighed against any safety considerations. Systematic efforts are being made by aca-demic researchers, Health Canada and the pharmaceutical industry to better define and address the problems of PRCA.

The importance of reporting adverse reactions to Health Canada or the manufacturer cannot be overstated. Health care practitioners are encouraged to familiarize themselves with the guidelines and mechanisms for adverse reaction reporting (see the Web site of the Canadian Adverse Reaction Monitoring Program, www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/index_adverse_e.html).

Carole Légaré Acting Director, Marketed Biologicals Biotechnology Products Division Christoper Turner Director General Marketed Health Products Directorate Anges V. Klein Manager Clinical Evaluation Division Biologics and Genetics Therapies Directorate Health Canada Ottawa, Ont.

Reference

  1. 1.↵
    Sibbald B. Eprex warning issued, but no ban. CMAJ 2004;170(5):778.
    OpenUrlFREE Full Text
  2. 2.↵
    Important drug safety information. Eprex (epoetin alfa) sterile solution. Revised prescribing information for patients with chronic renal failure [advisory on-line]. Ottawa: Health Canada; 2004 Jan 13. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/eprex3_hpc_e.html (accessed 2004 Jul 7).
  3. 3.↵
    Casadevaall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Epoetin alfa and pure red cell aplasia. Austr Adverse Drug React Bull [serial online] 2002;21(3). Available: www.tga.health.gov.au/adr/aadrb/aadr0208.htm#4 (accessed 2004 Apr 26).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (6)
CMAJ
Vol. 171, Issue 6
14 Sep 2004
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of Eprex in Canada
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Use of Eprex in Canada
Carole Légaré, Christopher Turner, Anges V. Klein
CMAJ Sep 2004, 171 (6) 552-553; DOI: 10.1503/cmaj.1041010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Use of Eprex in Canada
Carole Légaré, Christopher Turner, Anges V. Klein
CMAJ Sep 2004, 171 (6) 552-553; DOI: 10.1503/cmaj.1041010
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Reference
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Highlighting obesity as a risk factor for endometrial cancer
  • Hepatitis B vaccination for Canadian children: time for an adult conversation
  • Codesigning a public health approach to preventing firearm-related suicide deaths with rural communities
Show more Letters

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire